The clinical pharmacology of acamprosate

British Journal of Clinical Pharmacology

Volumn 77, Issue 2, 2014, Pages 315-323

  Kalk, Nicola J ^a   Lingford Hughes, Anne R ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

acamprosate; alcohol dependence; pharmacology

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ACAMPROSATE; BETA ENDORPHIN; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NALTREXONE;

ALCOHOL ABSTINENCE; ALCOHOL WITHDRAWAL; ALCOHOLISM; ANXIETY; AROUSAL; ARTICLE; BINGE EATING DISORDER; DIARRHEA; DRUG DOSE COMPARISON; DRUG INDICATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INSOMNIA; NEUROTRANSMISSION; NONHUMAN; PATHOLOGICAL GAMBLING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; TREATMENT OUTCOME;

ACAMPROSATE; ALCOHOL DEPENDENCE; PHARMACOLOGY;

ALCOHOL DETERRENTS; ALCOHOLISM; ANIMALS; HUMANS; RECURRENCE; RODENTIA; SUBSTANCE WITHDRAWAL SYNDROME; TAURINE;

EID: 84893042095     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12070     Document Type: Article

References (103)

1. Littleton J,. Acamprosate in alcohol dependence: how does it work? Addiction 1995; 90: 1179-1188.
2. Saivin S, Hulot T, Chabac S, Potgieter A, Durbin P, Houin G,. Clinical pharmacokinetics of acamprosate. Clin Pharmacokinet 1998; 35: 331-345.
3. Zornoza T, Cano-Cebrian MJ, Hipolito L, Granero L, Polache A,. Evidence of a flip-flop phenomenon in acamprosate pharmacokinetics: an in vivo study in rats. Biopharm Drug Dispos 2006; 27: 305-311.
4. Hammarberg A, Jayaram-Lindstrom N, Beck O, Franck J, Reid MS,. The effects of acamprosate on alcohol-cue reactivity and alcohol priming in dependent patients: a randomized controlled trial. Psychopharmacology (Berl) 2009; 205: 53-62.
5. Mason BJ, Goodman AM, Dixon RM, Hameed MH, Hulot T, Wesnes K, Hunter JA, Boyeson MG,. A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone. Neuropsychopharmacology 2002; 27: 596-606.
6. Johnson BA, O'Malley SS, Ciraulo DA, Roache JD, Chambers RA, Sarid-Segal O, Couper D,. Dose-ranging kinetics and behavioral pharmacology of naltrexone and acamprosate, both alone and combined, in alcohol-dependent subjects. J Clin Psychopharmacol 2003; 23: 281-293.
7. Rosenthal RN, Gage A, Perhach JL, Goodman AM,. Acamprosate: safety and tolerability in the treatment of alcohol dependence. J Addict Med 2008; 2: 40-50.
8. al Qatari M, Bouchenafa O, Littleton J,. Mechanism of action of acamprosate. Part II. Ethanol dependence modifies effects of acamprosate on NMDA receptor binding in membranes from rat cerebral cortex. Alcohol Clin Exp Res 1998; 22: 810-814.
9. Naassila M, Hammoumi S, Legrand E, Durbin P, Daoust M,. Mechanism of action of acamprosate. Part I. Characterization of spermidine-sensitive acamprosate binding site in rat brain. Alcohol Clin Exp Res 1998; 22: 802-809.
10. Harris BR, Prendergast MA, Gibson DA, Rogers DT, Blanchard JA, Holley RC, Hart SR, Scotland RL, Foster TC, Pedigo NW, Littleton JM,. Acamprosate inhibits the binding and neurotoxic effects of trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors. Alcohol Clin Exp Res 2002; 26: 1779-1793.
11. Boismare F, Daoust M, Moore N, Saligaut C, Lhuintre JP, Chretien P, Durlach J,. A homotaurine derivative reduces the voluntary intake of ethanol by rats: are cerebral GABA receptors involved? Pharmacol Biochem Behav 1984; 21: 787-789.
12. Berton F, Francesconi WG, Madamba SG, Zieglgansberger W, Siggins GR,. Acamprosate enhances N-methyl-D-apartate receptor-mediated neurotransmission but inhibits presynaptic GABA(B) receptors in nucleus accumbens neurons. Alcohol Clin Exp Res 1998; 22: 183-191.
13. Zeise ML, Kasparov S, Capogna M, Zieglgansberger W,. Acamprosate (calciumacetylhomotaurinate) decreases postsynaptic potentials in the rat neocortex: possible involvement of excitatory amino acid receptors. Eur J Pharmacol 1993; 231: 47-52.
14. Reilly MT, Lobo IA, McCracken LM, Borghese CM, Gong D, Horishita T, Harris RA,. Effects of acamprosate on neuronal receptors and ion channels expressed in Xenopus oocytes. Alcohol Clin Exp Res 2008; 32: 188-196.
15. Pierrefiche O, Daoust M, Naassila M,. Biphasic effect of acamprosate on NMDA but not on GABAA receptors in spontaneous rhythmic activity from the isolated neonatal rat respiratory network. Neuropharmacology 2004; 47: 35-45.
16. Daoust M, Legrand E, Gewiss M, Heidbreder C, DeWitte P, Tran G, Durbin P,. Acamprosate modulates synaptosomal GABA transmission in chronically alcoholised rats. Pharmacol Biochem Behav 1992; 41: 669-674.
17. Madamba SG, Schweitzer P, Zieglgansberger W, Siggins GR,. Acamprosate (calcium acetylhomotaurinate) enhances the N-methyl-D-aspartate component of excitatory neurotransmission in rat hippocampal CA1 neurons in vitro. Alcohol Clin Exp Res 1996; 20: 651-658.
18. Koob GF, Mason BJ, De Witte P, Littleton J, Siggins GR,. Potential neuroprotective effects of acamprosate. Alcohol Clin Exp Res 2002; 26: 586-592.
19. Popp RL, Lovinger DM,. Interaction of acamprosate with ethanol and spermine on NMDA receptors in primary cultured neurons. Eur J Pharmacol 2000; 394: 221-231.
20. Rammes G, Mahal B, Putzke J, Parsons C, Spielmanns P, Pestel E, Spanagel R, Zieglgänsberger W, Schadrack J,. The anti-craving compound acamprosate acts as a weak NMDA-receptor antagonist, but modulates NMDA-receptor subunit expression similar to memantine and MK-801. Neuropharmacology 2001; 40: 749-760.
21. Allgaier C, Franke H, Sobottka H, Scheibler P,. Acamprosate inhibits Ca2+ influx mediated by NMDA receptors and voltage-sensitive Ca2+ channels in cultured rat mesencephalic neurones. Naunyn Schmiedebergs Arch Pharmacol 2000; 362: 440-443.
22. Blednov YA, Harris RA,. Metabotropic glutamate receptor 5 (mGluR5) regulation of ethanol sedation, dependence and consumption: relationship to acamprosate actions. Int J Neuropsychopharmacol 2008; 11: 775-793.
23. Chau P, Hoifodt-Lido H, Lof E, Soderpalm B, Ericson M,. Glycine receptors in the nucleus accumbens involved in the ethanol intake-reducing effect of acamprosate. Alcohol Clin Exp Res 2010; 34: 39-45.
24. Erickson CA, Mullett JE, McDougle CJ,. Brief report: acamprosate in fragile X syndrome. J Autism Dev Disord 2010; 40: 1412-1416.
25. Dahchour A, De Witte P, Bolo N, Nedelec JF, Muzet M, Durbin P, Macher JP,. Central effects of acamprosate: part 1. Acamprosate blocks the glutamate increase in the nucleus accumbens microdialysate in ethanol withdrawn rats. Psychiatry Res 1998; 82: 107-114.
26. Dahchour A, De Witte P,. Ethanol and amino acids in the central nervous system: assessment of the pharmacological actions of acamprosate. Prog Neurobiol 2000; 60: 343-362.
27. Zalewska-Kaszubska J, Cwiek W, Dyr W, Czarnecka E,. Changes in the beta-endorphin plasma level after repeated treatment with acamprosate in rats selectively bred for high and low alcohol preference. Neurosci Lett 2005; 388: 45-48.
28. Umhau JC, Momenan R, Schwandt ML, Singley E, Lifshitz M, Doty L, Adams LJ, Vengeliene V, Spanagel R, Zhang Y, Shen J, George DT, Hommer D, Heilig M,. Effect of acamprosate on magnetic resonance spectroscopy measures of central glutamate in detoxified alcohol-dependent individuals: a randomized controlled experimental medicine study. Arch Gen Psychiatry 2010; 67: 1069-1077.
29. Kiefer F, Jahn H, Otte C, Nakovics H, Wiedemann K,. Effects of treatment with acamprosate on beta-endorphin plasma concentration in humans with high alcohol preference. Neurosci Lett 2006; 404: 103-106.
30. Hammarberg A, Nylander I, Zhou Q, Jayaram-Lindstrom N, Reid MS, Franck J,. The effect of acamprosate on alcohol craving and correlation with hypothalamic pituitary adrenal (HPA) axis hormones and beta-endorphin. Brain Res 2009; 1305: (Suppl.): S2-6.
31. Schule C, Laakmann G, Baghai T, Neukam C, Soyka M,. Lack of effects of acamprosate on anterior pituitary hormone secretion in healthy subjects. J Clin Psychopharmacol 1999; 19: 387-389.
32. Zimmerman U, Spring K, Koller G, Holsboer F, Soyka M,. Hypothalamic-pituitary-adrenal system regulation in recently detoxified alcoholics is not altered by one week of treatment with acamprosate. Pharmacopsychiatry 2004; 37: 98-102.
33. Lingford-Hughes A, Watson B, Kalk N, Reid A,. Neuropharmacology of addiction and how it informs treatment. Br Med Bull 2010; 96: 93-110.
34. Krystal JH, Staley J, Mason G, Petrakis IL, Kaufman J, Harris RA, Gelernter J, Lappalainen J,. Gamma-aminobutyric acid type A receptors and alcohol dependent: intoxication, dependence, vulnerability, and treatment. Arch Gen Psychiatry 2006; 63: 957-968.
35. Tsai G,. Glutamatergic neurotransmission in alcohol dependent. J Biomed Sci 1998; 5: 309-320.
36. Gewiss M, Heidbreder C, Opsomer L, Durbin P, De Witte P,. Acamprosate and diazepam differentially modulate alcohol-induced behavioural and cortical alterations in rats following chronic inhalation of ethanol vapour. Alcohol Alcohol 1991; 26: 129-137.
37. Spanagel R, Putzke J, Stefferl A, Schobitz B, Zieglgansberger W,. Acamprosate and alcohol: II. Effects on alcohol withdrawal in the rat. Eur J Pharmacol 1996; 305: 45-50.
38. Dahchour A, De Witte P,. Acamprosate decreases the hypermotility during repeated ethanol withdrawal. Alcohol 1999; 18: 77-81.
39. Cole JC, Littleton JM, Little HJ,. Acamprosate, but not naltrexone, inhibits conditioned abstinence behaviour associated with repeated ethanol administration and exposure to a plus-maze. Psychopharmacology (Berl) 2000; 147: 403-411.
40. Kotlinska J, Bochenski M,. The influence of various glutamate receptors antagonists on anxiety-like effect of ethanol withdrawal in a plus-maze test in rats. Eur J Pharmacol 2008; 598: 57-63.
41. Farook JM, Krazem A, Lewis B, Morrell DJ, Littleton JM, Barron S,. Acamprosate attenuates the handling induced convulsions during alcohol withdrawal in Swiss Webster mice. Physiol Behav 2008; 95: 267-270.
42. Le Magnen J, Tran G, Durlach J, Martin C,. Dose-dependent suppression of the high alcohol intake of chronically intoxicated rats by Ca-acetyl homotaurinate. Alcohol 1987; 4: 97-102.
43. Spanagel R, Holter SM, Allingham K, Landgraf R, Zieglgansberger W,. Acamprosate and alcohol: I. Effects on alcohol intake following alcohol deprivation in the rat. Eur J Pharmacol 1996; 305: 39-44.
44. Heyser CJ, Schulteis G, Durbin P, Koob GF,. Chronic acamprosate eliminates the alcohol deprivation effect while having limited effects on baseline responding for ethanol in rats. Neuropsychopharmacology 1998; 18: 125-133.
45. Czachowski CL, Delory MJ,. Acamprosate and naltrexone treatment effects on ethanol and sucrose seeking and intake in ethanol-dependent and nondependent rats. Psychopharmacology (Berl) 2009; 204: 335-348.
46. Grant KA, Woolverton WL,. Reinforcing and discriminative stimulus effects of Ca-acetyl homotaurine in animals. Pharmacol Biochem Behav 1989; 32: 607-611.
47. Spanagel R, Zieglgansberger W, Hundt W,. Acamprosate and alcohol: III. Effects on alcohol discrimination in the rat. Eur J Pharmacol 1996; 305: 51-56.
48. Rosner S, Hackl-Herrwerth A, Leucht S, Lehert P, Vecchi S, Soyka M,. Acamprosate for alcohol dependence. Cochrane Database Syst Rev 2010; (9) CD004332.
49. National Institute for Clinical Excellence. Alcohol Dependence and Harmful Alcohol Use. London: NICE, 2011.
50. Slattery J, Chick J, Cochrane M, Godfrey C, Kohli H, Macpherson K,. 2003) Prevention of relapse in alcohol dependence. Health Technology Assessment Report 3. Health Technology Board for Scotland, Glasgow. Prevention of relapse in alcohol dependence In: 3 HTAR, editor. Glasgow Health Technology Board for Scotland 2003.
51. Berglund M, Thelander S, Jonsson E,. Treating Alcohol and Drug Abuse. An Evidence Based Review. KGaAWeinheim: WILEY-VCH Verlag GmbH and Co, 2003.
52. Bouza C, Angeles M, Munoz A, Amate JM,. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction 2004; 99: 811-828.
53. Mann K, Lehert P, Morgan MY,. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol Clin Exp Res 2004; 28: 51-63.
54. Kranzler HR, Van Kirk J,. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res 2001; 25: 1335-1341.
55. Mason BJ, Ownby RL,. Acamprosate for the treatment of alcohol dependence: a review of double-blind, placebo-controlled trials. CNS Spectr 2000; 5: 58-69.
56. Rosner S, Leucht S, Lehert P, Soyka M,. Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes. J Psychopharmacol 2008; 22: 11-23.
57. Mason BJ, Heyser CJ,. The neurobiology, clinical efficacy and safety of acamprosate in the treatment of alcohol dependence. Expert Opin Drug Saf 2010; 9: 177-188.
58. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, Longabaugh R, Mason BJ, Mattson ME, Miller WR, Pettinati HM, Randall CL, Swift R, Weiss RD, Williams LD, Zweben A,; COMBINE Study Research Group. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 2006; 295: 2003-2017.
59. Mason BJ, Goodman AM, Chabac S, Lehert P,. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation. J Psychiatr Res 2006; 40: 383-393.
60. Morley KC, Teesson M, Reid SC, Sannibale C, Thomson C, Phung N, Weltman M, Bell JR, Richardson K, Haber PS,. Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomized, double-blind, placebo-controlled trial. Addiction 2006; 101: 1451-1462.
61. Garbutt JC, Kampov-Polevoy AB, Gallop R, Kalka-Juhl L, Flannery BA,. Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res 2010; 34: 1849-1857.
62. Verheul R, Lehert P, Geerlings PJ, Koeter MW, van den, Brink W,. Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients. Psychopharmacology (Berl) 2005; 178: 167-173.
63. Chick J, Lehert P, Landron F,. Does acamprosate improve reduction of drinking as well as aiding abstinence? J Psychopharmacol 2003; 17: 397-402.
64. Staner L, Boeijinga P, Danel T, Gendre I, Muzet M, Landron F, Luthringer R,. Effects of acamprosate on sleep during alcohol withdrawal: A double-blind placebo-controlled polysomnographic study in alcohol-dependent subjects. Alcohol Clin Exp Res 2006; 30: 1492-1499.
65. Perney P, Lehert P, Mason BJ,. Sleep disturbance in alcoholism: proposal of a simple measurement, and results from a 24-week randomized controlled study of alcohol-dependent patients assessing acamprosate efficacy. Alcohol Alcohol 2012; 47: 133-139.
66. Boeijinga PH, Parot P, Soufflet L, Landron F, Danel T, Gendre I, Muzet M, Demazières A, Luthringer R,. Pharmacodynamic effects of acamprosate on markers of cerebral function in alcohol-dependent subjects administered as pretreatment and during alcohol abstinence. Neuropsychobiology 2004; 50: 71-77.
67. Chick J, Howlett H, Morgan MY, Ritson B,. United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol 2000; 35: 176-187.
68. Mason BJ, Lehert P,. The effects of current subsyndromal psychiatric symptoms or past psychopathology on alcohol dependence treatment outcomes and acamprosate efficacy. Am J Addict 2010; 19: 147-154.
69. Schwartz TL, Siddiqui UA, Raza S, Costello A,. Acamprosate calcium as augmentation therapy for anxiety disorders. Ann Pharmacother 2010; 44: 1930-1932.
70. Lejoyeux M, Lehert P,. Alcohol-use disorders and depression: results from individual patient data meta-analysis of the acamprosate-controlled studies. Alcohol Alcohol 2011; 46: 61-67.
71. Gueorguieva R, Wu R, Donovan D, Rounsaville BJ, Couper D, Krystal JH, Krystal JH, O'Malley SS,. Baseline trajectories of drinking moderate acamprosate and naltrexone effects in the COMBINE study. Alcohol Clin Exp Res 2011; 35: 523-531.
72. Lingford-Hughes AR, Welch S, Peters L, Nutt DJ,. Evidence-based guidelines for the pharmacological management of substance misuse, addiction and comorbidity: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2012; 26: 1-54.
73. Ralevski E, O'Brien E, Jane JS, Dean E, Dwan R, Petrakis I,. Effects of acamprosate on cognition in a treatment study of patients with schizophrenia spectrum disorders and comorbid alcohol dependence. J Nerv Ment Dis 2010; 199: 499-505.
74. Tolliver BK, Desantis SM, Brown DG, Prisciandaro JJ, Brady KT,. A randomized, double-blind, placebo-controlled clinical trial of acamprosate in alcohol-dependent individuals with bipolar disorder: a preliminary report. Bipolar Disord 2012; 14: 54-63.
75. Mason BJ,. Acamprosate and naltrexone treatment for alcohol dependence: an evidence-based risk-benefits assessment. Eur Neuropsychopharmacol 2003; 13: 469-475.
76. Drummond DC,. Theories of drug craving, ancient and modern. Addiction 2001; 96: 33-46.
77. Kozlowski LT, Wilkinson DA,. Use and misuse of the concept of craving by alcohol, tobacco, and drug researchers. Br J Addict 1987; 82: 31-45.
78. World Health Organisation. Alcohol and Alcoholism: Report of An Expert Committee. Geneva: WHO, 1955; 94.
79. Paille FM, Guelfi JD, Perkins AC, Royer RJ, Steru L, Parot P,. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol 1995; 30: 239-247.
80. Sass H, Soyka M, Mann K, Zieglgansberger W,. Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry 1996; 53: 673-680.
81. Poldrugo F,. Acamprosate treatment in a long-term community-based alcohol rehabilitation programme. Addiction 1997; 92: 1537-1546.
82. Rubio G, Jimenez-Arriero MA, Ponce G, Palomo T,. Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment. Alcohol Alcohol 2001; 36: 419-425.
83. Tempesta E, Janiri L, Bignamini A, Chabac S, Potgieter A,. Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study. Alcohol Alcohol 2000; 35: 202-209.
84. Namkoong K, Lee BO, Lee PG, Choi MJ, Lee E,. Acamprosate in Korean alcohol-dependent patients: a multi-centre, randomized, double-blind, placebo-controlled study. Alcohol Alcohol 2003; 38: 135-141.
85. Richardson K, Baillie A, Reid S, Morley K, Teesson M, Sannibale C, Weltman M, Haber P,. Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol? Addiction 2008; 103: 953-959.
86. Umhau JC, Schwandt ML, Usala J, Geyer C, Singley E, George DT, Heilig M,. Pharmacologically induced alcohol craving in treatment seeking alcoholics correlates with alcoholism severity, but is insensitive to acamprosate. Neuropsychopharmacology 2011; 36: 1178-1186.
87. Ooteman W, Koeter MW, Verheul R, Schippers GM, van den, Brink W,. The effect of naltrexone and acamprosate on cue-induced craving, autonomic nervous system and neuroendocrine reactions to alcohol-related cues in alcoholics. Eur Neuropsychopharmacol 2007; 17: 558-566.
88. Nutt DJ, Lingford-Hughes A, Chick J,. Through a glass darkly: can we improve clarity about mechanism and aims of medications in drug and alcohol treatments? J Psychopharmacol 2012; 26: 199-204.
89. Brasser SM, McCaul ME, Houtsmuller EJ,. Alcohol effects during acamprosate treatment: a dose-response study in humans. Alcohol Clin Exp Res 2004; 28: 1074-1083.
90. Kratzer U, Schmidt WJ,. The anti-craving drug acamprosate inhibits the conditioned place aversion induced by naloxone-precipitated morphine withdrawal in rats. Neurosci Lett 1998; 252: 53-56.
91. McGeehan AJ, Olive MF,. The anti-relapse compound acamprosate inhibits the development of a conditioned place preference to ethanol and cocaine but not morphine. Br J Pharmacol 2003; 138: 9-12.
92. Kratzer U, Spanagel R, Schmidt WJ,. The effect of acamprosate on the development of morphine-induced behavioral sensitization in rats. Behav Pharmacol 2003; 14: 351-356.
93. Pechnick RN, Manalo CM, Lacayo LM, Vit JP, Bholat Y, Spivak I, Reyes KC, Farrokhi C,. Acamprosate attenuates cue-induced reinstatement of nicotine-seeking behavior in rats. Behav Pharmacol 2011; 22: 222-227.
94. McGeehan AJ, Olive MF,. Attenuation of cocaine-induced reinstatement of cocaine conditioned place preference by acamprosate. Behav Pharmacol 2006; 17: 363-367.
95. Bowers MS, Chen BT, Chou JK, Osborne MP, Gass JT, See RE, Bonci A, Janak PH, Olive MF,. Acamprosate attenuates cocaine- and cue-induced reinstatement of cocaine-seeking behavior in rats. Psychopharmacology (Berl) 2007; 195: 397-406.
96. Kampman KM, Dackis C, Pettinati HM, Lynch KG, Sparkman T, O'Brien CP,. A double-blind, placebo-controlled pilot trial of acamprosate for the treatment of cocaine dependence. Addict Behav 2011; 36: 217-221.
97. Dannon PN, Rosenberg O, Schoenfeld N, Kotler M,. Acamprosate and Baclofen were Not Effective in the Treatment of Pathological Gambling: Preliminary Blind Rater Comparison Study. Front Psychiatry 2011; 2: 1-4.
98. Black DW, McNeilly DP, Burke WJ, Shaw MC, Allen J,. An open-label trial of acamprosate in the treatment of pathological gambling. Ann Clin Psychiatry 2011; 23: 250-256.
99. Stanley BG, Willett VL 3rd, Donias HW, Dee MG, 2nd, Duva MA,. Lateral hypothalamic NMDA receptors and glutamate as physiological mediators of eating and weight control. Am J Physiol 1996; 270 (2 Pt 2): R443-449.
100. Hermanussen M, Tresguerres JA,. A new anti-obesity drug treatment: first clinical evidence that, antagonising glutamate-gated Ca2+ ion channels with memantine normalises binge-eating disorders. Econ Hum Biol 2005; 3: 329-337.
101. Brennan BP, Roberts JL, Fogarty KV, Reynolds KA, Jonas JM, Hudson JI,. Memantine in the treatment of binge eating disorder: an open-label, prospective trial. Int J Eat Disord 2008; 41: 520-526.
102. Han DH, Lyool IK, Sung YH, Lee SH, Renshaw PF,. The effect of acamprosate on alcohol and food craving in patients with alcohol dependence. Drug Alcohol Depend 2008; 93: 279-283.
103. McElroy SL, Guerdjikova AI, Winstanley EL, O'Melia AM, Mori N, McCoy J, Keck PE Jr, Hudson JI,. Acamprosate in the treatment of binge eating disorder: a placebo-controlled trial. Int J Eat Disord 2011; 44: 81-90.